Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Dec;63(12):e164-e171.
doi: 10.1111/epi.17427. Epub 2022 Oct 14.

Successful treatment of adult Dravet syndrome patients with cenobamate

Konstantin L Makridis  1   2   3   4 , Anna-Lena Friedo  5 , Christoph Kellinghaus  6 , Florian-Phillip Losch  7 , Bettina Schmitz  7 , Christian Boßelmann  8 , Angela M Kaindl  1   2   3   4
Affiliations
Multicenter Study

Successful treatment of adult Dravet syndrome patients with cenobamate

Konstantin L Makridis et al. Epilepsia. 2022 Dec.

Abstract

Dravet syndrome (DS) is a rare, drug-resistant, severe developmental and epileptic encephalopathy caused by pathogenic variants in the α subunit of the voltage-gated sodium channel gene SCN1A. Hyperexcitability in DS results from loss of function in inhibitory interneurons. Thus sodium channel blockers are usually contraindicated in patients with DS as they may lead to disease aggravation. Cenobamate (CNB) is a novel antiseizure medication (ASM) with promising rates of seizure freedom in patients with focal-onset, drug-resistant epilepsy. CNB blocks persistent sodium currents by promoting the inactive states of sodium channels. In a multi-center study, we analyzed retrospectively the effect of an add-on therapy of CNB in adult patients with DS. We report four adult patients with DS in whom the use of CNB resulted in a significant seizure reduction of more than 80%, with a follow-up of up to 542 days. CNB was the first drug in these patients that resulted in a long-lasting and significant seizure reduction. No severe adverse events occurred. We highlight CNB as an ASM that may lead to a clinically meaningful reduction of seizure frequency in adult patients with DS. It is unclear, however, if all patients with DS benefit, requiring further investigation and functional experiments.

Keywords: SCN1A; Dravet syndrome; antiseizure medication; cenobamate; epilepsy; treatment.

PubMed Disclaimer

References

REFERENCES

    1. Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52(Suppl 2):3-9.
    1. Česká K, Český L, Ošlejšková H, Aulická Š. The direct costs of Dravet's syndrome before and after diagnosis assessment. Neuropediatrics. 2021;52:6-11.
    1. Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia. 2011;52(Suppl 2):72-5.
    1. Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum mutat. 2015;36:928-30.
    1. Berecki G, Bryson A, Terhag J, Maljevic S, Gazina EV, Hill SL, et al. SCN1A gain of function in early infantile encephalopathy. Ann neurol. 2019;85:514-25.

Publication types

LinkOut - more resources